Analyst Ratings February 12, 2026

H.C. Wainwright Trims Neurocrine Bio. Price Target to $192, Keeps Buy Rating

Analyst cuts target modestly after 2025 momentum; 2026 Ingrezza guidance and price-access trade-offs cited as drivers

By Derek Hwang NBIX
H.C. Wainwright Trims Neurocrine Bio. Price Target to $192, Keeps Buy Rating
NBIX

H.C. Wainwright reduced its price target for Neurocrine Biosciences (NASDAQ: NBIX) to $192 from $198 while retaining a Buy rating. The firm said the adjustment follows a strong finish to 2025, with record Ingrezza prescriptions and a successful launch year for Crenessity, but noted that 2026 guidance for Ingrezza of $2.7-2.8 billion - roughly 10% growth - was temporarily disappointing. The research house attributed the cautious outlook to possible net price headwinds tied to deliberate "price-for-access" decisions ahead of 2027 IRA effects, rather than weaker commercial uptake. H.C. Wainwright lowered its revenue assumptions for Ingrezza and trimmed its view of Crenessity penetration, prompting the target cut, even as key opinion leaders continue to describe Crenessity positively. Separately, Neurocrine reported fourth-quarter 2025 results that beat consensus for both EPS and revenue.

Key Points

  • H.C. Wainwright lowered its price target on Neurocrine Biosciences to $192 from $198 and retained a Buy rating.
  • Neurocrine closed 2025 with record Ingrezza prescriptions and a successful Crenessity launch, but guided 2026 Ingrezza sales to $2.7-2.8 billion (~10% growth), which H.C. Wainwright described as momentarily disappointing.
  • Neurocrine beat consensus on Q4 2025 results with EPS of $1.88 (vs $1.86 est.) and revenue of $805.5 million (vs $802.45 million est.).

Analyst action and rationale

H.C. Wainwright lowered its price target for Neurocrine Biosciences (NASDAQ: NBIX) to $192.00 from $198.00 on Thursday, while keeping a Buy rating on the shares. The firm said the modest reduction in the target stems from updated modeled revenue potential for Ingrezza and a revised expectation for Crenessity's market penetration.

Performance through 2025 and near-term guidance

The firm highlighted Neurocrine's strong finish to 2025, noting record prescription volumes for Ingrezza and what it characterized as a successful first year for Crenessity's launch. Despite that momentum, H.C. Wainwright described Neurocrine's 2026 sales guidance for Ingrezza - projected at $2.7-2.8 billion, or roughly 10% year-over-year growth - as "momentarily disappointing."

Driver of the cautious outlook

H.C. Wainwright said the conservatism in the 2026 outlook appears to be driven by potential net price headwinds. The research note attributes those headwinds to strategic "price-for-access" trade-offs the company may make ahead of expected impacts from the 2027 IRA, rather than signaling any weakness in the commercial uptake of Ingrezza.

Model revisions and clinical perception

As a result of revising revenue assumptions for Ingrezza and adjusting the expected penetration rate for Crenessity, the firm trimmed its target price. At the same time, H.C. Wainwright emphasized that conversations with key opinion leaders continue to reinforce Crenessity's strong clinical profile, describing it in the note as a clinical "wonder drug."

Quarterly financials

In separate company disclosures, Neurocrine reported fourth-quarter 2025 results that exceeded consensus estimates. The company posted EPS of $1.88 versus an expected $1.86, and revenue of $805.5 million compared with an expected $802.45 million. While some stock movement followed the earnings release, those intraday price actions are not the focus of this report.

Other items

No material mergers or acquisitions were reported in the recent updates, and the note did not provide further details on other analyst ratings or additional company developments beyond those summarized above.


Key contextual points

  • H.C. Wainwright reduced its NBIX price target to $192 from $198 while maintaining a Buy rating.
  • Neurocrine ended 2025 with record Ingrezza prescriptions and a successful launch year for Crenessity, yet guided to $2.7-2.8 billion for Ingrezza in 2026.
  • Q4 2025 results beat expectations: EPS $1.88 (vs $1.86 est.) and revenue $805.5 million (vs $802.45 million est.).

Risks and uncertainties

  • Potential net price headwinds stemming from "price-for-access" trade-offs could limit near-term revenue growth for Ingrezza - a concern for the pharmaceutical and healthcare sectors.
  • Revised revenue and penetration assumptions for Ingrezza and Crenessity introduce uncertainty around future cash flow projections, relevant to equity and biotech investors.
  • Limited disclosure on other analyst views and absence of material M&A activity in the updates mean broader market sentiment and strategic direction remain partially opaque.

Risks

  • Potential net price headwinds tied to "price-for-access" trade-offs ahead of 2027 IRA impacts could weigh on Ingrezza revenue - affecting the pharmaceutical and healthcare sectors.
  • Revisions to revenue potential for Ingrezza and Crenessity penetration rates create uncertainty for future revenue forecasts - relevant to equity investors in biotech.
  • Limited disclosure on broader analyst ratings and no reported significant M&A leave strategic visibility and market sentiment partially unclear.

More from Analyst Ratings

HSBC Lowers Synopsys Rating to Hold, Flags 2026 as Transition Year Feb 21, 2026 DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026